Business
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026JELMYTO achieved $21.7 million in revenue in Q1 2026, representing year-over-year growth of 7%Continued advancement of next-generation pipeline, UGN-103 on track for NDA submission in the second half of 2026; six-month durability data expected in mid-2026UroGen to host Key Opinion Leader (KOL) panel highlighting r
About this update from Urogen Pharma Ltd.
[{"type":"image","alt":"UroGen Pharma Ltd.","displaySize":"","headline":null,"caption":"UroGen Pharma Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/17a882b70e8712b054a21e7ea3661787"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gfSsx4lS3V0xpLK4VA4i6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMw--/https://media.zenfs.com/en/globenewswire.com/17a882b70e8712b054a21e7ea3661787","width":300,"height":88}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026","length":185,"tagName":"p"}]},{"val":[{"type":"text","content":"JELMYTO achieved $21.7 million in revenue in Q1 2026, representing year-over-year growth of 7%","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"Continued advancement of next-generation pipeline, UGN-103 on track for NDA submission in the second half of 2026; six-month durability data expected in mid-2026","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"UroGen to host Key Opinion Leader (KOL) panel highlighting real-world experience with ZUSDURI at the American Urological Association (AUA) annual meeting on May 17th at 8:30 AM ET","length":179,"tagName":"p"}]},{"val":[{"type":"text","content":"Conference call and webcast to be held today at 10:00 AM ET","length":59,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":683,"olType":false},{"type":"text","content":"PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2026, and provided an overview of recent developments.","length":339,"tagName":"p"},{"type":"text","content":"“2026 is off to a strong start, with expanding usage of ZUSDURI™ (mitomycin) for intravesical solution and clear acceleration across key commercial indicators, including prescriber trial and adoption,” said Liz Barrett, President and Chief Executive Officer of UroGen. “These trends reflect growing clinical confidence in ZUSDURI as a primary, non-surg...